Other novel compounds in clinical development comprise ZW25 (Zanidatamab), a bispecific antibody directed toward two different HER2 epitopes representing the binding sites of Trastuzumab and Pertuzumab, which has shown promising efficacy in preclinical models of different HER2+ cancers [43]. Here, ERBB2 is linked to cancer.